Millions of people live with this chronic autoimmune condition, watching their skin cycle through painful flares and brief periods of calm
It has become a cross-disciplinary practice , shaped by clinical innovation, patient demand, and the rapid expansion of digital healthcare
Follow & subscribe Matthew Laubers Post : Weight-loss drugs are evolving Bimagrumab, a mAb that blocks activin type II receptors, was originally investigated for musclewasting diseases, but it's now gaining traction in obesity treatment, especially when paired with GLP1 agonists
Second, study designs are formally similar, but there are some differences
You can have 30-day or 90-day check-in cadences, async portal check-ins, or live video/phone visits